The feasibility of a novel therapeutic strategy using angiogenic growth factors to expedite and/or augment collateral artery development has recently entered the realm of treatment of ischemic diseases. Hepatocyte growth factor (HGF) is a novel member of endothelium-specific growth factors whose mitogenic activity on endothelial cells is very potent. Although it has been demonstrated that HGF is a potential angiogenic growth factor in in vitro culture systems, there is no direct in vivo evidence for the angiogenic activity of HGF in physiological conditions. In this study, we hypothesized that transfection of HGF gene into infarcted myocardium could induce angiogenesis, potentially resulting in a beneficial response to hypoxia. Human HGF gene or control vector driven by the SR␣ promoter was transfected into rat myocardium by the HVJ-liposome method. Four days after in vivo transfection of human HGF gene, there was a marked increase in human immunoreactive HGF as compared with control vector (P Ͻ 0.01). In myocardium transfected with HGF vector, a significant increase in PCNA-positive endothelial cells was observed, while few PCNA-positive endothelial cells were detected in both control-vector-transfected and untreated myocardium. The number of vessels around
Introduction
Recent progress in molecular biology has led to the development of gene therapy [1] [2] [3] as a new strategy to treat a variety of cardiovascular diseases. Targeted diseases range from single gene deficiency diseases to more complex diseases in adults, such as restenosis after angioplasty. One obvious major target in the field of gene therapy is cardiac diseases, including myocardial infarction and cardiomyopathy. Recent reports have described that the administration of basic fibroblast growth factor (b-FGF) the HGF injection sites was significantly increased as compared with control vector or vehicle (P Ͻ 0.01). Angiogenic activity induced by the transfection of HGF vector was also confirmed by the activation of a transcription factor, ets, which is essential for angiogenesis. Furthermore, we studied the pathophysiological role of HGF in a myocardial infarction model. The concentration of endogenous HGF was significantly decreased in infarcted myocardium. Therefore, we hypothesized that transfection of HGF gene into infarcted myocardium could induce a beneficial response to the decreased endogenous HGF. Indeed, transfection of human HGF into infarcted myocardium also resulted in a significant increase in the number of vessels (P Ͻ 0.01), accompanied by marked induction of ets binding activity and a significant increase in blood flow. Overall, the present results provide direct in vivo evidence for the induction of angiogenesis by transfection of the human HGF gene in rat non-infarcted and infarcted myocardium. The constant production of local HGF resulting from the transgene may be considered as an innovative therapeutic angiogenesis strategy for ischemic diseases such as myocardial infarction. Gene Therapy (2000) 7, 417-427. or vascular endothelial growth factor (VEGF) into the pericardium salvaged infarcted myocardium via formation of neovasculature. 4, 5 The expression of angiogenic factors (as exemplified by basic and acidic fibroblast growth factor, TGF-␤ and vascular endothelial growth factor) due to gene transfer might induce neovascularization, resulting in the salvage of the infarcted myocardium. As we have previously reported successful gene transfer in a myocardial infarction model, 6, 7 we reasoned that transfection of angiogenic growth factor genes is a potential gene therapy for myocardial infarction.
We have focused on hepatocyte growth factor (HGF), which is a mesenchyme-derived pleiotropic factor that regulates cell growth, cell motility, and morphogenesis in various types of cells. Also HGF is considered a humoral mediator of epithelial-mesenchymal interactions respon-sible for morphogenic tissue interactions during the period of embryonic development and organogenesis. 8, 9 Recently, HGF has been reported as a mitogen exclusively for endothelial cells without the replication of vascular smooth muscle cells (VSMC), [10] [11] [12] [13] thereby indicating it as a potential angiogenic growth factor. Indeed, activation of the HGF system promoted angiogenesis in a Matrigel system, 14 however, this system provides far from physiological conditions. Thus, there is no direct in vivo evidence of the angiogenic action of HGF. Moreover, HGF and its specific receptor, c-met, are expressed in the heart and blood vessels including endothelial cells and vascular smooth muscle cells. 15 In this study, we addressed two specific issues, to examine the feasibility of gene therapy for myocardial infarction: (1) whether over-expressed HGF in non-infarcted and infarcted myocardium induces neovascularization; and (2) what molecular mechanisms are involved in angiogenesis induced by overexpression of HGF.
Results
In vivo transfection of human HGF into non-infarcted myocardium To examine the effect of HGF gene transfected into the myocardium, we first measured human immunoreactive HGF in non-infarcted myocardium transfected with human HGF vector or control vector at 4 days after transfection. As shown in Figure 1a , human immunoreactive HGF was readily detected in myocardium transfected with human HGF vector, by EIA using specific human anti-HGF antibody that did not cross-react with rat HGF, while human HGF could not be detected in myocardium transfected with control vector. Similarly, human HGF could not be detected in untransfected myocardium. Interestingly, rat endogenous immunoreactive HGF concentration was significantly increased in myocardium transfected with human HGF vector, as assessed by EIA using specific rat anti-HGF antibody at 4 days after transfection (Figure 1b ). These data suggest that endogenous cardiac HGF was induced by overexpressed exogenous HGF.
Angiogenesis induced by human HGF gene transfer
Given the successful in vivo transfer of human HGF vector into the myocardium, the proliferation of endothelial cells was measured at 4 days after transfection by immunohistochemical analysis using PCNA staining, to determine the mitogenic action of locally produced human HGF. The transfection of human HGF vector significantly increased PCNA-stained endothelial cells (a marker of DNA synthesis) in the myocardium around the injection site as compared with myocardium transfected with control vector (Figure 2a) . The PCNA-positive cells were identified as endothelial cells, but not fibroblasts or cardiac myocytes, as assessed by HE staining and endothelium-specific staining with endothelial cell specific antibody (RECA). In intact normal hearts, less than 1% of endothelial cells in the myocardium stained positively for PCNA by immunohistochemical technique (data not shown). As shown in Figure 2b , the number of PCNApositive stained endothelial cells was significantly increased in myocardium transfected with human HGF vector as compared with control vector-transfected myocardium and untransfected myocardium (P Ͻ 0.01). Next, we measured the number of vessels at 14 days after transfection. Of importance, the number of vessels was significantly increased in myocardium transfected with HGF vector as compared with control vector (P Ͻ 0.01), as shown in Figures 3a and b . However, for angiogenesis to have therapeutic feasibility, the size of neovascularized vessels is important. Therefore, we also counted the number of vessels, according to the size. Microvessels less than 10 m were significantly increased in myocardium transfected with HGF gene (Figure 3b ). In addition to microvessels, vessels more than 10 m were also significantly increased in myocardium transfected with HGF vector, as shown in Figure 3b . These results indicate that the angiogenesis induced by HGF could produce small-to-medium sized vessels as well as microcapillary vessels. 
Gene Therapy
Up-regulation of essential transcription factor for angiogenesis, ets, by HGF To confirm further the induction of angiogenesis by in vivo transfection of HGF gene, an essential transcription factor for angiogenesis, ets-1, was analyzed. Transfection of HGF vector caused a large increase in ets activity in myocardium transfected with HGF vector, which was assessed by gel mobility shift assay (Figure 4) . Moreover, complete competition for the increased binding of ets-1 by an excess amount of cold ets-1 probe was observed (Figure 4a ). Densitometric analysis revealed a significant increase in ets-1 binding activity in myocardium transfected with HGF vector as compared with control vector (P Ͻ 0.01, Figure 4b ). To investigate the localization of up-regulated ets-1 binding activity, we also performed immunohistochemical analysis. Immunohistochemical studies showed little staining in myocardium transfected with control vector and untransfected myocardium. In contrast, in myocardium transfected with human HGF vector, positive staining of ets-1 was observed in endothelial cells and VSMC around neovascularized vessels ( Figure 5 ).
Induction of angiogenesis by overexpressed HGF in myocardial infarction model
Given the strong angiogenic activity of the overexpression of human HGF, we further studied the physiological role of overexpressed HGF in a myocardial infarction model. Thus, we measured the endogenous cardiac HGF level in infarcted myocardium. Of importance, cardiac immunoreactive rat HGF was significantly decreased at 14 days after myocardial infarction (P Ͻ 0.01, Figure 6b ), as compared with that in the sham-operated rat. Therefore, we concluded that transfection of HGF gene into the infarcted myocardium could induce a beneficial response to the decreased endogenous HGF. Importantly, the expression of transfected HGF was sustained at least up to 14 days after transfection ( Figure 6a ). Interestingly, transfection of human HGF vector significantly increased rat endogenous cardiac HGF (Figure 6b ). Moreover, a significant increase in the number of vessels was observed in the myocardium transfected with human HGF vector as compared with that in control vector at 14 days after transfection (P Ͻ 0.01, Figure 7 ), accompanied by induction of ets binding activity ( Figure  8 ). Similar to the experiments in non-infarcted myocardium, microvessels less than 10 m were significantly increased in myocardium transfected with HGF gene. In addition to microvessels, vessels more than 10 m were also significantly increased in myocardium transfected with HGF vector (Figure 7b ). Moreover, a marked increase in blood flow was observed using a laser Doppler perfusion imager in infarcted myocardium transfected with HGF vector ( Figure 9 ). Although blood flow in infarcted myocardium was markedly decreased as compared with non-infarcted myocardium, the overexpression of HGF significantly attenuated the decrease in blood flow in infarcted myocardium ( Figure 10 , P Ͻ 0.05).
Discussion
HGF has been postulated to be a potent angiogenic growth factor, since it is a mitogen for various endothelial cells and is also a potent inducer of tube formation. Indeed, the angiogenic response to HGF has been reported in an experimental model of implanted reconstituted basement membrane (Matrigel).
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14 However, no report has described the angiogenic activity of HGF in physiological conditions in a normal tissue without any supplement such as Matrigel, and in addition, there are controversial reports that HGF was unable to stimulate angiogenesis. 16 Here, we demonstrated direct in vivo evidence of angiogenesis induced by HGF in non-infarcted and infarcted myocardium. The specificity of the angiogenic effect of in vivo transfection of HGF gene into the myocardium is supported by several lines of evidence: (1) human HGF protein was increased by the transfection of human HGF vector; (2) an increase in the number of vessels and PCNA-positive stained endothelial cells was observed in myocardium transfected with HGF vector; (3) induction of an essential transcription factor for angiogenesis, ets-1, by transfection of HGF vector was observed. More importantly, the current study demonstrated a significant increase in blood flow by the overexpression of HGF even in infarcted myocardium. These data clearly reveal the potential utility of HGF gene transfer for the treatment of ischemic heart disease.
Members of the ets family play important roles in regulating gene expression in response to multiple developmental and mitogenic signals. [17] [18] [19] [20] The ets family of transcription factors has a DNA-binding domain in common that binds to a core GGA(A/T) DNA sequence. 21, 22 In situ hybridization studies have shown that the proto-oncogene c-ets is expressed in endothelial cells at the beginning of blood vessel formation, under normal and pathological conditions. 23, 24 Thus, previous reports suggest that the ets family may activate the transcription of genes encoding collagenase 1, stromelysine 1 and urokinase plasminogen activator, which are proteases involved in extracellular matrix degradation. [25] [26] [27] It is believed that the ets family takes part in regulating angiogenesis by controlling the transcription of these genes whose activity is necessary for the migration of endothelial cells from pre-existing capillaries. In this study, we also demonstrated the up-regulation of endogenous HGF expression by exogenously transfected HGF gene, consistent with our previous findings in in vitro experiments. 28 Induction of ets activity by overexpressed HGF may regulate this auto-loop up-regulation of HGF, since the promoter region of the HGF gene contains a number of putative Gene Therapy regulatory elements, such as a B cell-and macrophagespecific transcription factor binding site (PU.1/ETS), besides an interleukin-6 response element (IL-6 RE), a TGF-beta inhibitory element (TIE), and a cAMP response element (CRE).
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VEGF, another endothelium-specific growth factor, has been reported to be up-regulated by hypoxia in vitro and by ischemia in vivo. [30] [31] [32] Therefore, VEGF is a likely mediator in the natural process of ischemia-induced myocardial neovascularization. In the clinical setting, the VEGF induced as a potent angiogenesis factor may not be sufficient to stimulate coronary collateral formation, therefore, administration of recombinant VEGF or VEGF genes to promote angiogenesis will be useful as a treatment for arteriosclerosis obliterans (ASO) and myocardial infarction in animal models and clinical patients. 5, 33, 34 On the other hand, the present data demonstrated that endogenously expressed HGF was markedly decreased in infarcted myocardium in the late phase (14 days), although the up-regulation of c-met has been previously reported in a myocardial infarction model in the acute phase. 35 Therefore, a sufficient supply of HGF by in vivo transfer of HGF gene into the infarcted myocardium would also enhance collateral formation. Of importance, the overexpression of HGF also has the ability to induce angiogenesis in a myocardial infarction model, in addition to noninfarcted myocardium. Taken together, overexpression of HGF might enhance angiogenesis in myocardial infarction. Since the size of myocardial infarction correlates closely with mortality and residual impairment of function in survivors, 36 a therapy targeted at promoting collateral formation would decrease the size of chronic myocardial infarction. Indeed, the beneficial effect of HGF gene transfer was also reported by Ueda et al. 37 They demonstrated that transfection of HGF gene into transplanted hearts resulted in the attenuation of reperfusion injury. 37 In addition, we have previously reported the anti-apoptotic action of HGF in endothelial cells. 38 Although it is likely that gene transfer of HGF may also work as an anti-apoptotic factor in the myocardial infarction model, further studies are necessary.
The current studies suggest a novel therapeutic strategy that might reduce the extent of myocardial infarction, utilizing in vivo transfer of HGF gene, through the induction of coordinated transactivating gene, ie ets-1, which is necessary for angiogenesis. In this study, we employed direct injection into the noninfarcted and infarcted myocardium, since we have previously reported no evidence of cytotoxicity or inflammation caused by the HVJ-liposome complex itself. 6, 7, 39 Moreover, we have established an efficient in vivo gene transfer method into the heart using the HVJ-liposome method via direct infusion into a coronary artery as well as incubation within the pericardium, without any damage to the myocardium. 6 The widespread transgene expression obtained by these approaches suggests that neovascularization induced by the overexpression of HGF gene may be useful for the treatment of ischemic heart disease.
In conclusion, manipulation of the formation of new vessels by means of the overexpression of HGF is likely to provide new therapeutic options in angiogenesisdependent conditions such as wound healing, inflammatory diseases, peripheral vascular disease and ischemic heart disease, such as myocardial infarction.
Materials and methods

Construction of plasmids
To produce a HGF expression vector, human HGF cDNA (2.2 kb) was inserted into the EcoRI and NotI sites of pUC-SR␣ expression vector plasmid. In this plasmid, transcription of HGF cDNA was under the control of the SR␣ promoter.
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Preparation of HVJ-liposome
We have previously reported a high efficacy of transfection with hemagglutinating virus of Japan (HVJ)-coated liposomes. 6, 7, 39, 42, 43 Briefly, phosphatidylserine, phosphatidylcholine, and cholesterol were mixed at a weight ratio of 1:4.8:2 in tetrahydrofuran. The lipid mixture (10 mg) was deposited on the sides of a flask by removal of the solvent in a rotary evaporator. The high mobility group (HMG)-1 purified from calf thymus was mixed with plasmid DNA (300 g) in 200 l balanced salt solution (BSS; 137 mm NaCl, 5.4 mm KCl, 10 mm Tris-HCl, pH 7.6) at 20°C for 1 h, and then the mixture was added to the dried lipid. Liposome-DNA-HMG 1 complex suspension was mixed by vortex, sonication for 3 s, and shaking for 30 min. Purified HVJ (Z strain) was inactivated by UV irradiation (110 erg/mm 2 /s) for 3 min immediately before use. The liposome suspension (0.5 ml, containing 10 mg lipid) was mixed with HVJ (20 000 hemagglutinating units) in a total volume of 4 ml BSS. The mixture was incubated at 4°C for 10 min and then for 30 min with gentle shaking at 37°C. Free HVJ was removed from the HVJ-liposomes by sucrose density gradient centrifugation. The top layer of the sucrose gradient containing the HVJ-liposome-DNA complex was collected and used immediately.
In vivo gene transfer using direct injection approach Sprague-Dawley rats (400-500 g; Charles River Breeding Laboratories, Boston, MA, USA) were anesthetized with an intraperitoneal injection of sodium pentobarbital (0.1 ml/100 mg). Rats were intubated and connected to a respirator. HVJ-liposome complex containing human HGF or control vector (10 g/ml in liposomes) was injected directly into the apex of the non-infarcted heart with a 30 G needle through a left lateral thoracotomy. Then 10 l (0.1 g plasmid) HVJ-liposome complex was injected into each rat. 6 ,7,39 a 
Figure 7 Effect of the transfection of HGF vector on the vascular formation in a myocardial infarction model. (a) Representative cross-sections: HGF (+), the infarcted myocardium from rats transfected with human HGF vector (× 200); HGF (−), the infarcted myocardium from rats transfected with control vector (× 200). Long arrows indicate vessels more than
Measurement of HGF concentration in myocardium
To document successful transfection of HGF vector into the myocardium, we examined the production of human immunoreactive HGF. 15, 44 Four days after the transfection, the hearts were perfused with saline, promptly taken away removing excess fat, frozen in liquid nitrogen, and then stored at −70°C. On the day of the extraction, the tissue was thawed at 4°C, weighed, and homogenized by polytron in an assay solution. Each specimen was centrifuged at 20 000 g for 30 min at 4°C, to remove the lysates. The concentration of HGF in the myocardium was determined by the enzyme-immunoassay with an anti-human HGF antibody, as described previously. 11, 15 Briefly, a rabbit anti-rat or an anti-human HGF IgG was coated on 96-well plates (Corning, NY, USA) at 4°C for 15 h. After blocking with 3% bovine serum albumin in phosphate-buffered saline (PBS), the conditioned medium was added to each well. Afterwards, the preparation was incubated for 2 h at 25°C. Wells were washed three times with PBS containing 0.025% Tween 20 (PBSTween). A biotinylated rabbit anti-human HGF IgG was added and the preparation was incubated for 2 h at 25°C. After the wash with PBS-Tween, wells were incubated with a horseradish peroxidase-conjugated streptavidinbiotin complex in PBS-Tween. The enzyme reaction was Gene Therapy initiated by adding substrate solution composed of 2.5 mg/ml o-phenylenediamine, 100 mm sodium phosphate, 50 mm citric acid, and 0.015% H 2 O 2 . The enzyme reaction was suspended by adding 1 m H 2 SO 4 , and the absorbance was measured at 490 nm of wavelength. The antibody against human HGF reacts with only human HGF, not with rat HGF. 44 Immunohistochemical studies Monoclonal antibodies against endothelial specific RECA (1A4, Dako, Glostup, Denmark) and proliferating cell nuclear antigen (PCNA) (PC-10, Dako) were used as specific markers for endothelial cells and proliferating cells, respectively, in paraffin-embedded sections. Also, antiets-1 (Santa Cruz, Santa Cruz, CA, USA) antibody was used to analyze the expression of ets-1 induced by the transfection of HGF gene. Immunohistochemical staining was performed using the immunoperoxidase avidinbiotin complex system with nickel chloride (NiCl) color modification as previously described. 45 Briefly, 5-m sections were deparaffinized, rehydrated before blocking the endogenous peroxidase activity with 3% hydrogen peroxidase, and preincubated with 5% normal rabbit serum in Tris-HCl buffered saline (TBS) for 20 min. Diluted primary antibodies (1A4 1:50, PC-10 1:500, anti-ets-1 1:20) 
P-labeled ets probe and an excess amount of non-labeled ets probe (competitor) (× 50).
were then applied to the sections, and these sections were incubated for 30 min. With intervening washing in TBS, they were serially incubated with a 1:400 dilution of biotinylated rabbit, anti-mouse IgG (Dako) in TBS for 30 min; streptavidin-biotinylated horseradish peroxidase complex (Dako), diluted 1:100 in TBS for 30 min; 0.05% 3,3Ј-diaminobenzidine (DAB, Sigma Chemicals, St Louis, MO, USA) in 200 ml TBS to which had been added 0.2 ml 30% hydrogen peroxide and 1.0 ml 8% NiCl solution for 5 min. Sections were counterstained with methylgreen, dehydrated in a graded series of alcohol concentrations, permeated with xylene, and then covered with a coverslip.
To analyze the number of vessels in the non-infarcted and the infarcted myocardium transfected with HGF vector or control vector, HE staining was performed. Two weeks after the transfection, rats were killed and the hearts were removed after perfusion-fixation (110 mmHg) with 10% buffered formalin. Three individual sections from the middle of the transfected myocardium were analyzed. The number of vessels was counted under a light microscopy (magnification, × 100) in a blinded manner, after selective staining with hematoxylin-eosin in a standard manner. The total number of vascules in each section was summed and expressed as number per section. At least 10 individual sections were evaluated on each heart. The areas, in which the number of vascules was quantified, were randomly selected in the injected site and around the injected site. The animals were coded so that the analysis was performed without any knowledge of which treatment each individual had received. The reproducibility of the results was assessed. Intraobserver variability was determined from triplicate measurements performed by one observer for all sections. The mean ± s.d. difference among measurements made by the same observer was 2.8 ± 0.5%. Interobserver variability was determined from measurements of 10 randomly selected sections performed by the second observer in addition to the first one. The numerical difference between the measurements made by two observers was 3.1 ± 0.6%. These observers were blinded to other data concerning the rats, as well as to the results of other observers.
Gel mobility shift assay Rats were killed 1 week after the transfection, and the nuclear extracts were prepared from the non-infarcted and the infarcted myocardium transfected with HGF vector or control vector, as previously described. 44, 45 In brief, rat hearts were homogenized with a Potte-Elvehjem homogenizer in 4 volumes of ice-cold homogenization buffer (10 mm Hepes (pH 7.5), 0.5 m sucrose, 0.5 mm spermidine, 0.15 mm spermin, 5 mm EDTA, 0.25 m EGTA, 7 mm beta-mercaptoethanol and 1 mm phenylmethylsulfonyl-fluoride). After the centrifugation at 12 000 g for 30 min at 4°C, each pellet was lysed in 1 volume of icecold homogenization buffer containing 0.1% NP-40 by homogenizing in a Dounce homogenizer. Then it was centrifuged at 12 000 g for 30 min at 4°C and the pellet nucleus was washed twice with ice-cold buffer containing 0.35 m sucrose. After washing, the nucleus was preextracted with 1 volume of ice-cold homogenization buffer containing 0.05 m NaCl and 10% glycerol for 15 min at 4°C. The nucleus was then extracted with homogenization buffer containing 0.3 m NaCl and 10% glycerol for 1 h at 4°C. Subsequently, the concentration of DNA was adjusted to 1 mg/ml. After pelleting the extracted nucleus at 12 000 g for 30 min at 4°C, 45% (NH 4 ) 2 SO 4 was added to the supernatant. Then, the mixture was stirred for 30 min at 4°C. The precipitated protein was collected at 17 000 g for 30 min, resuspended in homogenization buffer containing 0.35 m sucrose, and stored in aliquots at −70°C.
ODNs containing ets binding sites (5Ј-GTGCCG GGGTAGGAAGTGGGCTGGG-3Ј; only sense strands are shown) and mutated ets binding sites (5Ј-GTGCCGGGGTAccttGTGGGCTGGG-3Ј; underline shows mutated sequences) were labeled as a primer at the 3Ј end by 3Ј end-labeling kit (Clontech, Palo Alto, CA, USA). After end-labeling, 32 P-labeled ODNs were purified by the application to Nick column (Pharmacia, Uppsala, Sweden). The binding mixtures (10 l) including 32 P-labeled primers (0.5-1 ng, 10 000-15 000 c.p.m.) and 1 g polydeoxyinosinic-deoxycytidic acid (Sigma, St Louis, MO, USA) were incubated with 10 g nuclear extract for 30 min at room temperature and then loaded on to 5% polyacrylamide gel. The gels were subjected to electrophoresis, dried and pre-incubated with parallel samples for 10 min before the addition of the labeled probe. As a control, samples were incubated with an excess (50 ×, 100 ×) of nonlabeled ets-1 ODN which completely abolished binding. Gels were analyzed by autoradiography.
In vivo gene transfer using a direct injection approach to a myocardial infarction model For a myocardial infarction model, the left coronary artery (LCA) was ligated within 2 to 3 mm of the proxi- Gene Therapy mal aorta. 6, 46, 47 Ventricular premature beats, ventricular tachycardia, and ventricular fibrillation occurred after ligation and ST segment elevation was also detected on the ECG. All examined animals had a normal P-QRS coupling and exhibited normal sinus rhythm with an anesthetized heart rate of approximately 400 beats per minute. Recanalization and reperfusion were not performed. Immediately after ligation, HVJ-liposome complex containing either human HGF or control vector (10 g/ml in liposomes) was directly injected into the infarcted area with a 30 G needle through a left lateral thoracotomy. The volume of HVJ-liposome injected into the rats was 10 l (0.1 g plasmid). 6, 7, 39 The rats were killed at either 3 h or 14 days after the ligation for the analysis of RT-PCR, EIA and HE staining.
Monitoring cardiac blood flow
The measurement of blood flow with a laser Doppler imager (LDI) has been previously described. 48, 49 As it was clearly demonstrated that laser Doppler flow velocity correlates well with the capillary density, 48, 49 we measured the cardiac blood flow by means of a laser Doppler blood flow meter (Laser Doppler Image, Moor Instruments, Devon, UK). Indeed, we confirmed that the blood flow measured by LDI correlated well with the capillary den-sity (data not shown). LDI uses a 12-mW helium-neon laser beam that sequentially scans a 5 × 5 cm surface area with extremely high speed to be able to measure the blood flow in the myocardium. The blood flow at 1 mm under the surface can be measured. While scanning, blood cells that are in motion shift with the frequency of projection light according to the Doppler principle. Upon the termination of scanning, a color-coded image representing blood flow distribution is displayed on a monitor. The perfusion signal is subdivided into 14 different intervals and each interval is displayed in a separate color. Low or no perfusion is displayed as dark blue, whereas the highest perfusion intervals is displayed as white. The stored perfusion values behind the colorcoded pixels remain available for data analysis. Before measuring, rats were anesthetized, intubated and connected to a respirator. Then, the chest was widely opened through a left lateral thoracotomy to scan the surface of the heart directly. Perfusion analyses were performed sequentially: (1) the non-infarcted myocardium transfected with control vector; (2) the non-infarcted myocardium transfected with HGF vector; (3) the infarcted myocardium transfected with control vector; and (4) the infarcted myocardium transfected with HGF vector at 14 days after ligation and transfection. These laser images were quantitatively converted into histograms that represented the amount of blood flow on the x-axis and the number of pixels on the y-axis in the traced area. The average blood flow in each histogram was evaluated.
Statistical analysis
All values are expressed as mean ± s.e.m. The analysis of variance with a subsequent Duncan's test was used to determine the significance of differences in the multiple comparisons. The differences with values of less than 0.05 were considered significant.
